What side effects are associated with this type of intervention?

Common treatments for plaque psoriasis, such as TNF-alpha inhibitors (e.g., etanercept, adalimumab), IL-12/23 inhibitors (e.g., ustekinumab), and other systemic therapies (e.g., methotrexate), have various side effects. TNF-alpha inhibitors can cause infections, injection site reactions, and potential cardiovascular risks. IL-12/23 inhibitors may lead to upper respiratory infections, headache, and fatigue. Methotrexate is associated with liver toxicity, bone marrow suppression, and gastrointestinal issues. These treatments aim to reduce inflammation and immune response but require monitoring for adverse effects.

What prior FDA approvals exist?

The FDA has approved several treatments for plaque psoriasis that target specific pathways involved in its pathogenesis. These include biologics such as ustekinumab, which targets interleukins IL-12 and IL-23, and TNF-alpha inhibitors like etanercept and adalimumab. Small molecule inhibitors like apremilast, a phosphodiesterase 4 (PDE4) inhibitor, have also been approved. These treatments aim to modulate the immune response and reduce inflammation, similar to the approach likely being studied with DC-806.

What other types of research exist?

Promising novel alternatives to DC-806 for plaque psoriasis patients in 2024 include: 1) VTP-38543, a topical treatment that improves epidermal barrier features and is safe and well-tolerated. 2) CRA-680, an antagonist of CRTH2, which has shown efficacy in allergic inflammatory diseases and could be relevant for psoriasis. These alternatives target different aspects of the inflammatory process and may offer new therapeutic options.

← Back to Search

Other

DC-806 for Plaque Psoriasis (Illuminate Trial)

Phase 2

Waitlist Available

Research Sponsored by DICE Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Summary

This trial is testing a new oral medication called DC-806. It targets people with moderate to severe plaque psoriasis. The study will check how well the medication works, its safety, and how the body processes it.

Who is the study for?

Adults aged 18-70 with moderate to severe plaque psoriasis, who have had it for at least 6 months and are candidates for phototherapy or systemic therapy. They must have a BMI of 18-40 kg/m2 and agree to use effective contraception. Exclusions include certain abnormal lab values, recent flares or infections, history of significant mental health issues, strong drug interactions, heart abnormalities, chronic infections like HIV/hepatitis/TB, cancer in the last 5 years (except some skin cancers), or no response to specific psoriasis treatments.

What is being tested?

The trial is testing DC-806's effectiveness and safety compared to a placebo over a period of 12 weeks. Participants will be randomly assigned to receive either multiple oral doses of DC-806 or a placebo in double-blind fashion (neither participants nor researchers know who receives which treatment). The study also looks into how the body processes the drug.

What are the potential side effects?

While not specified here, common side effects for new psoriasis medications can include symptoms like nausea, diarrhea, headache, fatigue and potential risks for infection due to immune system impact. Specific side effects related to DC-806 would be detailed based on previous research phases.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

5Treatment groups

Experimental Treatment

Placebo Group

Group I: Treatment Group 4: DC-806 Dose DExperimental Treatment1 Intervention

Group II: Treatment Group 3: DC-806 Dose CExperimental Treatment1 Intervention

Group III: Treatment Group 2: DC-806 Dose BExperimental Treatment1 Intervention

Group IV: Treatment Group 1: DC-806 Dose AExperimental Treatment1 Intervention

Group V: Treatment Group 5: PlaceboPlacebo Group1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

DC-806

2023

Completed Phase 2

~300

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for Plaque Psoriasis include TNF-alpha inhibitors, IL-12/23 inhibitors, and small molecules targeting specific pathways. TNF-alpha inhibitors reduce inflammation by blocking the tumor necrosis factor-alpha, a cytokine involved in systemic inflammation. IL-12/23 inhibitors target interleukins 12 and 23, which are crucial in the inflammatory process of psoriasis. Small molecules like DC-806, which are being studied, often inhibit specific enzymes or receptors involved in the pathogenesis of psoriasis, such as phosphodiesterase-4 (PDE4) inhibitors. These treatments are important for patients as they help reduce the chronic inflammation and abnormal skin cell growth characteristic of Plaque Psoriasis, leading to improved skin appearance and reduced symptoms.

Investigation on the Mechanism of Qubi Formula in Treating Psoriasis Based on Network Pharmacology.Trim21 promotes inflammation in keratinocytes of psoriatic patients.The Psoriasis Therapeutic Potential of a Novel Short Laminin Peptide C16.